Stock Scorecard



Stock Summary for Emergent Biosolutions Inc (EBS) - $5.88 as of 5/13/2025 8:29:10 PM EST

Total Score

11 out of 30

Safety Score

38 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for EBS

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for EBS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for EBS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for EBS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for EBS (38 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for EBS

Emergent Biosolutions ( EBS ) Q1 Earnings Top Estimates 5/7/2025 9:35:00 PM
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health - Emergent BioSolutions ( NYSE:EBS ) 5/1/2025 9:07:00 PM
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health 5/1/2025 9:07:00 PM
NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario - NurExone Biologic ( OTC:NRXBF ) 4/22/2025 8:05:00 PM
Axsome ( AXSM ) Moves 4.2% Higher: Will This Strength Last? 4/10/2025 1:52:00 PM
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? 4/9/2025 12:45:00 PM
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 3/20/2025 8:30:00 PM
Hikma announces Health Canada approval of KLOXXADO® ( naloxone HCl ) Nasal Spray 8 mg 3/20/2025 12:06:00 PM
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International 3/19/2025 8:30:00 PM
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - Emergent BioSolutions ( NYSE:EBS ) 3/19/2025 8:30:00 PM

Financial Details for EBS

Company Overview

Ticker EBS
Company Name Emergent Biosolutions Inc
Country USA
Description Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 5.88
Price 4 Years Ago 43.47
Last Day Price Updated 5/13/2025 8:29:10 PM EST
Last Day Volume 994,216
Average Daily Volume 1,307,586
52-Week High 15.10
52-Week Low 4.02
Last Price to 52 Week Low 46.27%

Valuation Measures

Trailing PE N/A
Industry PE 29.04
Sector PE 49.22
5-Year Average PE -0.35
Free Cash Flow Ratio 3.21
Industry Free Cash Flow Ratio 19.04
Sector Free Cash Flow Ratio 31.82
Current Ratio Most Recent Quarter 3.69
Total Cash Per Share 1.83
Book Value Per Share Most Recent Quarter 8.89
Price to Book Ratio 0.53
Industry Price to Book Ratio 38.21
Sector Price to Book Ratio 30.58
Price to Sales Ratio Twelve Trailing Months 0.30
Industry Price to Sales Ratio Twelve Trailing Months 93.50
Sector Price to Sales Ratio Twelve Trailing Months 25.54
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 54,278,000
Market Capitalization 319,154,640
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.79%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 2.20%
Annual Earnings Growth 74.94%
Reported EPS 12 Trailing Months -3.60
Reported EPS Past Year 0.71
Reported EPS Prior Year -0.94
Net Income Twelve Trailing Months -190,600,000
Net Income Past Year -190,600,000
Net Income Prior Year -760,500,000
Quarterly Revenue Growth YOY -29.60%
5-Year Revenue Growth -1.73%
Operating Margin Twelve Trailing Months -2.21%

Balance Sheet

Total Cash Most Recent Quarter 99,500,000
Total Cash Past Year 99,500,000
Total Cash Prior Year 111,700,000
Net Cash Position Most Recent Quarter -564,200,000
Net Cash Position Past Year -564,200,000
Long Term Debt Past Year 663,700,000
Long Term Debt Prior Year 446,500,000
Total Debt Most Recent Quarter 663,700,000
Equity to Debt Ratio Past Year 0.42
Equity to Debt Ratio Most Recent Quarter 0.42
Total Stockholder Equity Past Year 482,800,000
Total Stockholder Equity Prior Year 649,300,000
Total Stockholder Equity Most Recent Quarter 482,800,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 35,800,000
Free Cash Flow Per Share Twelve Trailing Months 0.66
Free Cash Flow Past Year 35,800,000
Free Cash Flow Prior Year -257,900,000

Options

Put/Call Ratio 0.06
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.09
MACD Signal -0.06
20-Day Bollinger Lower Band 2.35
20-Day Bollinger Middle Band 7.27
20-Day Bollinger Upper Band 12.19
Beta 2.09
RSI 57.74
50-Day SMA 8.13
150-Day SMA 9.53
200-Day SMA 18.53

System

Modified 5/12/2025 10:42:14 PM EST